The FDA picked the LP.8.1 Covid strain for the fall vaccines, fueling concerns that the shots may be limited to only the most ...

In view of the recent surge in COVID-19 cases in various parts of the country, the Delhi government has issued an advisory ...

Low uptake may reflect barriers—misinformation, access or shifting insurance coverage—not simply waning need.

FDA's new COVID-19 vaccine policy may restrict low-risk individuals' access, pending clinical trials to prove benefits.

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.

Health Minister Pankaj Kumar Singh confirmed that authorities are verifying whether these patients are Delhi residents or ...

The FDA will encourage new clinical trials on the widely used vaccines before approving them for children and healthy adults.

On May 22, an FDA advisory committee unanimously recommended COVID-19 vaccine manufacturers target the JN.1 variant in their formulations.  The Vaccines and Related Biological Products Advisory ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

Vaccine advisers to the FDA decided Thursday that only strains of the JN.1 variant should be targeted by updated versions of covid vaccines that will be available next fall and winter. Separately, ...

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

The US FDA may limit Covid-19 boosters to high-risk groups only, citing lack of efficacy in healthy individuals. Meanwhile, ...